Pressmeddelande

BioStock: Spago Nanomedical starts phase IIa study in endometriosis

Cision Publicerad: 06 Dec 2022 08:28

Lund-based Spago Nanomedical has recently been given the go-ahead to initiate a phase IIa study with the product candidate SN132D for the diagnosis of the widespread disease endometriosis. Patient recruitment has already begun and the company expects to be able to include the first patient shortly. BioStock talked to CEO Mats Hansen about the new area and the upcoming study, but also about the SPAGOPIX-01 study in breast cancer that recently was concluded.

Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/12/spago-nanomedical-starts-phase-iia-study-in-endometriosis/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Spago Nanomedical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!